Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes

Simple item page
dc.citation.epage1723en_US
dc.citation.issueNumber6en_US
dc.citation.spage1715en_US
dc.citation.volumeNumber32en_US
dc.contributor.authorErikçi, E.en_US
dc.contributor.authorGursel, M.en_US
dc.contributor.authorGürsel, T.en_US
dc.date.accessioned2016-02-08T09:54:37Z
dc.date.available2016-02-08T09:54:37Z
dc.date.issued2011en_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractThe immunogenicity of a vaccine formulation is closely related to the effective internalization by the innate immune cells that provide prolonged and simultaneous delivery of antigen and adjuvant to relevant antigen presenting cells. Endosome associated TLR9 recognizes microbial unmethylated CpG DNA. Clinical applications of TLR9 ligands are significantly hampered due to their pre-mature in vivo digestion and rapid clearance. Liposome encapsulation is a powerful tool to increase in vivo stability as well as enhancing internalization of its cargo to relevant immune cells. The present study established that encapsulating CpG motifs in different liposomes having different physicochemical properties altered not only encapsulation efficiency, but also the release and delivery rates that ultimately impacted in vitro and ex-vivo cytokine production rates and types. Moreover, different liposomes encapsulating CpG ODN significantly increased Th1-biased cytokines and chemokines gene transcripts Additional studies demonstrated that co-stimulatory and surface marker molecules significantly upregulated upon liposome/CpG injection. Finally, co-encapsulating model antigen ovalbumin with CpG ODN adjuvant in nanoliposomes profoundly augmented Th1 and cell mediated anti-Ova specific immune response. Collectively, this work established an unappreciated immunoregulatory property of nanoliposomes mediating immunity against protein antigen and could be harnessed to design more effective therapeutic vaccines or stand alone immunoprotective agents targeting infectious diseases, as well as cancer or allergy. © 2010 Elsevier Ltd.en_US
dc.description.provenanceMade available in DSpace on 2016-02-08T09:54:37Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 70227 bytes, checksum: 26e812c6f5156f83f0e77b261a471b5a (MD5) Previous issue date: 2011en
dc.identifier.doi10.1016/j.biomaterials.2010.10.054en_US
dc.identifier.issn0142-9612
dc.identifier.urihttp://hdl.handle.net/11693/22040
dc.language.isoEnglishen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.biomaterials.20http://dx.doi.org/10.10.054en_US
dc.source.titleBiomaterialsen_US
dc.subjectCpG DNAen_US
dc.subjectImmune responseen_US
dc.subjectLiposomesen_US
dc.subjectNanotechnologyen_US
dc.subjectTLRen_US
dc.subjectVaccineen_US
dc.subjectImmunologyen_US
dc.titleDifferential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomesen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes.pdf
Size:
621.97 KB
Format:
Adobe Portable Document Format
Description:
Full printable version
Download

Collections

Scholarly Publications - Molecular Biology and Genetics